GlassScriptPhysician profile
Matthew S Kane
NPI 1235198847
$576,664.61
in general payments reported to CMS, 2019-2025
61 companies · $46K in 2025
The $46K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162K · 2020: $102K · 2021: $77K · 2022: $66K · 2023: $59K · 2024: $67K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $154K · Food and Beverage: $8,481 · Travel and Lodging: $8,223 · Education: $87.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $154,381.25 |
| Food and Beverage | $8,481.29 |
| Travel and Lodging | $8,222.90 |
| Education | $87.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $478,935.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $50,131.37 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21,295.15 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $14,170.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $3,077.39 | 2019-2025 | |
| Medtronic, INC. | $2,551.11 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Signia |
| Sanofi-Aventis U.S. LLC | $788.85 | 2019-2025 | |
| Amgen INC. | $593.18 | 2019-2025 | Evenity, Prolia, Repatha |
| Tandem Diabetes Care, INC. | $466.68 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $451.40 | 2019-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $372.17 | 2019-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $347.80 | 2019-2025 | Tirosint, Licart, Licart |
| Mannkind Corporation | $248.43 | 2022-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $238.41 | 2021-2025 | |
| Amarin Pharma, INC. | $222.88 | 2019-2023 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $213.81 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $186.85 | 2022-2024 | Recorlev, Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $174.62 | 2019-2025 | Strensiq |
| Insulet Corporation | $168.86 | 2019-2024 | Omnipod |
| Cequr Corporation | $161.51 | 2021-2024 | Cequr Simplicity |
| Radius Health, INC. | $150.75 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $144.25 | 2019-2022 | |
| Companion Medical, INC. | $111.10 | 2019-2020 | |
| Corcept Therapeutics | $108.52 | 2019-2024 | Korlym |
| Merck Sharp & Dohme LLC | $96.77 | 2019-2023 | Steglujan, Steglatro, Segluromet |
| Antares Pharma, INC. | $83.94 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Ascensia Diabetes Care US INC. | $80.41 | 2022-2024 | |
| Kyowa Kirin, INC. | $77.65 | 2023-2024 | Crysvita |
| Vivus LLC | $70.97 | 2019-2024 | Pancreaze, Qsymia |
| Acella Pharmaceuticals, LLC | $68.01 | 2022-2024 | NP Thyroid 60 |
| Lifescan, INC. | $60.59 | 2019-2022 | |
| Becton, Dickinson and Company | $57.25 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $50.50 | 2023-2024 | Isturisa, Signifor Lar |
| Shire North American Group INC | $49.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.42 | 2022-2024 | |
| Tolmar, INC. | $48.16 | 2023-2025 | Jatenzo |
| Pfizer INC. | $47.93 | 2019-2024 | |
| Amphastar Pharmaceuticals, INC. | $39.32 | 2024-2025 | |
| Nevro Corp. | $33.25 | 2022 | |
| Currax Pharmaceuticals LLC | $32.87 | 2020-2022 | |
| Esperion Therapeutics, INC. | $32.60 | 2020-2024 | Nexletol |
| Ascendis Pharma Endocrinology INC | $27.63 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $27.51 | 2019 | |
| Embecta Corp. | $26.51 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.96 | 2023 | Cycloset |
| Zealand Pharma US, INC. | $21.61 | 2021 | |
| Beta Bionics, INC. | $21.51 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Neurocrine Biosciences, INC. | $20.13 | 2025 | |
| Bigfoot Biomedical INC | $20.01 | 2022 | |
| Amryt Pharma Holdings LTD | $19.98 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.42 | 2022 | |
| Horizon Therapeutics Plc | $17.78 | 2021 | |
| Sequel Med Tech, LLC | $17.69 | 2025 | Twiist |
| Nalpropion Pharmaceuticals LLC | $17.02 | 2019 | |
| Intra-Sana Laboratories | $16.77 | 2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Eisai INC. | $15.44 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.47 | 2023 | Adthyza |
| Kowa Pharmaceuticals America, INC. | $13.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.71 | 2020 | |
| Opko Pharmaceuticals, LLC | $12.58 | 2019 | |
| Valeritas, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.